Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Capital Expenditures (2016 - 2023)

Spyre Therapeutics' Capital Expenditures history spans 9 years, with the latest figure at -$2.1 million for Q3 2023.

  • For Q3 2023, Capital Expenditures fell 206800.0% year-over-year to -$2.1 million; the TTM value through Dec 2023 reached -$2.1 million, down 5536.84%, while the annual FY2022 figure was $38000.0, 93.37% down from the prior year.
  • Capital Expenditures reached -$2.1 million in Q3 2023 per SYRE's latest filing, down from $1000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.4 million in Q1 2020 to a low of -$2.1 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $18571.4, with a median of $66000.0 recorded in 2019.
  • Peak YoY movement for Capital Expenditures: surged 1077.12% in 2020, then plummeted 206800.0% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $1.2 million in 2019, then plummeted by 124.79% to -$291000.0 in 2020, then skyrocketed by 289.0% to $550000.0 in 2021, then plummeted by 99.82% to $1000.0 in 2022, then tumbled by 206800.0% to -$2.1 million in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Capital Expenditures are -$2.1 million (Q3 2023), $1000.0 (Q3 2022), and $37000.0 (Q1 2022).